Hematology is in our blood

Boule Diagnostics AB is a company with a strong heritage when it comes to hematology diagnostics. We developed the very first European blood cell counter, and today our instruments, reagents, calibrators and controls are used by healthcare providers around the world. Boule’s products are currently on sale in more than 100 countries.

Our blood tests help provide one of the first and most important indicators of a disease state and Boule systems play an increasingly important role in helping build the infrastructure of healthcare for small and medium size patient care environments in both human and veterinary markets.

Boule is listed on NASDAQ Stockholm since June 2011.

Interview with Boules CEO Fredrik Dalborg answering questions about Q1.

Financial Calendar

Year-end report                                                           2019-02-07

Annual report 2018                                                     2019-04-15

Interim report Q1                                                         2019-05-06

Annual General Meeting 2019                                 2019-05-06

Interim report Q2                                                         2019-08-14

Interim report Q3                                                         2019-10-30




Welcome to visit us at Medlab

4-7 February,
Dubai International Convention and Exhibition Centre, Dubai, UAE

Booth no.Z5.B48


Company in figures 2017


Net sales, SEK million
(increased by 8%)


Operating profit, SEK million
(increased by 15%)

0 %

Gross margin
(decreased by 1%)

0 %

Equity/assets ratio
(same as 2016)